860 related articles for article (PubMed ID: 16841178)
21. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology.
Conner P; Skoog L; Söderqvist G
Climacteric; 2001 Mar; 4(1):7-12. PubMed ID: 11379380
[TBL] [Abstract][Full Text] [Related]
22. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women.
Murkes D; Conner P; Leifland K; Tani E; Beliard A; Lundström E; Söderqvist G
Fertil Steril; 2011 Mar; 95(3):1188-91. PubMed ID: 21067727
[TBL] [Abstract][Full Text] [Related]
23. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
Holtorf K
Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
[TBL] [Abstract][Full Text] [Related]
24. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
25. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
27. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.
Murkes D; Lalitkumar PG; Leifland K; Lundström E; Söderqvist G
Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():12-5. PubMed ID: 22834417
[TBL] [Abstract][Full Text] [Related]
28. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
Mueck AO; Seeger H; Wallwiener D
Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
[TBL] [Abstract][Full Text] [Related]
30. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells.
Krämer EA; Seeger H; Krämer B; Wallwiener D; Mueck AO
Eur J Obstet Gynecol Reprod Biol; 2006 Nov; 129(1):77-83. PubMed ID: 16460873
[TBL] [Abstract][Full Text] [Related]
31. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
[TBL] [Abstract][Full Text] [Related]
32. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
33. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
Hofseth LJ; Raafat AM; Osuch JR; Pathak DR; Slomski CA; Haslam SZ
J Clin Endocrinol Metab; 1999 Dec; 84(12):4559-65. PubMed ID: 10599719
[TBL] [Abstract][Full Text] [Related]
34. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
35. The effect of low dose hormone therapy on mammographic breast density.
Christodoulakos GE; Lambrinoudaki IV; Vourtsi AD; Vlachou S; Creatsa M; Panoulis KP; Botsis D
Maturitas; 2006 Apr; 54(1):78-85. PubMed ID: 16198519
[TBL] [Abstract][Full Text] [Related]
36. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels.
Bernardi F; Pluchino N; Pieri M; Begliuomini S; Lenzi E; Puccetti S; Casarosa E; Luisi M; Genazzani AR
Neuroendocrinology; 2006; 83(5-6):348-59. PubMed ID: 16931878
[TBL] [Abstract][Full Text] [Related]
37. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
Speroff L
Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
[TBL] [Abstract][Full Text] [Related]
38. Effects of sex steroids on proliferation in normal mammary tissue.
Söderqvist G
Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
[TBL] [Abstract][Full Text] [Related]
39. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
40. Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women.
Lalitkumar PGL; Lundström E; Byström B; Ujvari D; Murkes D; Tani E; Söderqvist G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
